Zimmer Biomet Q2 Earnings Call Highlights

2 weeks ago 15

MarketBeat

Sun, August 9, 2026 astatine 1:03 PM CDT 6 min read

Key Points

Interested successful Zimmer Biomet Holdings, Inc.? Here are 5 stocks we similar better.
Zimmer Biomet reported coagulated Q2 growth: Net income roseate 4.8% to $2.177 billion, driven by hips, specialty businesses and technology. Adjusted EPS was $2.07, portion U.S. integrated income accrued 4.6%.
Technology and hep products led performance: Hip income grew 5.1%, portion technology, data, bony cement and surgical income surged 21.5%, supported by beardown ROSA, TMINI and OrthoGrid adoption. Knee income were astir flat, with planetary weakness—especially successful China—offsetting U.S. gains.
Zimmer Biomet raised its 2026 outlook: Organic income maturation is present expected astatine 2.25% to 3.25%, and adjusted EPS guidance accrued to $8.47-$8.59. The institution besides plans up to $1 cardinal successful stock repurchases this year, contempt borderline unit from costs and investments successful its U.S. income organization.

A Closer Look astatine Healthcare Sector Earnings: AZN vs. EW vs. ZBH

Zimmer Biomet (NYSE:ZBH) reported second-quarter 2026 nett income of $2.177 billion, up 4.8% connected a reported ground and 4.0% connected an integrated constant-currency basis, arsenic maturation successful hips, specialty businesses and exertion helped offset weaker show successful definite different merchandise lines.

U.S. integrated constant-currency income roseate 4.6%, portion planetary income accrued 3.1%. Chairman, President and CEO Ivan Tornos said the U.S. effect reflected advancement successful the company's sales-force transformation, merchandise launches and commercialized execution.

→ Sandisk Just Delivered a Blowout Quarter—Here's Why the Stock Is Falling

Intuitive Surgical Leads the Pack successful Robotic Surgery Innovation

GAAP diluted net per stock accrued to $1.03 from $0.77 a twelvemonth earlier. Adjusted EPS was $2.07, unchanged from the prior-year quarter. Interim CFO Paul Stellato said higher gross and a little stock number were offset by expected dilution from the Paragon 28 acquisition and investments successful the U.S. commercialized organization.

Hips, Technology Drive Growth

Hip income grew 5.1% connected a constant-currency basis, including 5.9% maturation successful the United States and 4.2% internationally. Tornos attributed U.S. hep show to adoption of the company's "triple play" offering: the Z1 Triple Taper Hip Stem, the HAMMR surgical impactor and OrthoGrid navigation exertion for nonstop anterior hep procedures.

→ No Hangover: Revisiting Microsoft One Week After Earnings

2 Robotic Surgery Stocks Challenging Intuitive Surgical's Lead

Z1 present accounts for much than 40% of Zimmer Biomet's U.S. hep systems, according to Tornos, portion HAMMR was utilized successful much than 25% of U.S. superior hep cases. OrthoGrid recorded its strongest 4th to date, with first-half lawsuit measurement matching its full-year 2025 level.

Read Entire Article